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A combined therapy of the alkylating agent temozolomide (TMZ) and radiotherapy is
standard treatment, and it improves the survival of patients with newly diagnosed
glioblastoma (GBM). The DNA repair enzyme O6-methylguanine-DNA methyltransferase
(MGMT) removes the most cytotoxic lesions generated by TMZ, O6-methylguanine,
establishingMGMT as one of the most important DNA repair mechanisms of TMZ-induced
DNA damage. Thus, the expression of MGMT, its activity, and its promoter methylation
status are associated with the response of GBM to TMZ, confirming that MGMT promotes
clinical resistance to TMZ. Previous studies have shown that a variety of drugs such as
interferon-β (IFN-β), levetiracetam (LEV), resveratrol, and valproic acid (VAP) increased the
sensitivity of TMZ through MGMT-dependent or MGMT-independent mechanisms. In this
review, we describe drugs and promising molecules that influence the responsiveness of
GBM to TMZ and discuss their putative mechanism of action. In MGMT-positive GBMs,
drugs that modulate MGMT activity could enhance the therapeutic activity of TMZ. Thus,
administration of these drugs as an adjunct to TMZ chemotherapy may have clinical
applications in patients with malignant gliomas to improve the outcome.
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INTRODUCTION
Glioblastoma (GBM) is the most common and lethal among
all gliomas. The current standard of care includes surgery fol-
lowed by concomitant radiation and chemotherapy with the oral
DNA-alkylating agent with good penetration into the blood-brain
barrier, temozolomide (TMZ). O6-methylguanine-DNA methyl-
transferase (MGMT) repairs the most cytotoxic lesions generated
by TMZ, O6-methylguanine. Accordingly, increased expression of
MGMT is one of the most robust predictors of the TMZ response
in malignant glioma cells. The most important mechanism of
silencing of the MGMT gene is methylation of its promoter,
resulting in the loss of MGMT expression and diminished DNA
repair activity. Therefore, the epigenetic silencing of MGMT gene
by its promoter methylation has been shown to be a useful pre-
dictor of responsiveness of GBM patients to TMZ (Hegi et al.,
2005).
Because tumor cells that express MGMT are more resistant
to TMZ, targeting the MGMT activity can enhance the ther-
apeutic efficiency of TMZ. Recently, a phase III clinical trial
examined the effects of dose-dense TMZ as a strategy to deplete
MGMT and enhance the outcome in GBM patients (RTOG0525,
ASCO 2011). In addition, preclinical studies and clinical trials
are investigating whether it is possible to increase the anti-
cancer potency of TMZ by combining it with other pharma-
cological agents (Goellner et al., 2011; Agnihotri et al., 2012).
In this review, we discuss drugs that modulate the therapeutic
efficacy of TMZ via MGMT-dependent or MGMT-independent
mechanisms.
MGMT-DEPENDENTMECHANISM
Methylation of the MGMT promoter in GBM patients correlates
with increased susceptibility of the tumor to the alkylating agent
therapy. Several drugs have been reported to induce methylation
of the MGMT promoter, resulting in increased TMZ cytotoxicity.
O6-BENZYLGUANINE (O6-BG)
O6-benzylguanine (O6-BG), a low-molecular-weight substrate,
can irreversibly inactivate MGMT, by competing with O6-
methylguanine. in vitro (Dolan et al., 1991; Bobola et al., 1996)
and in vivo (Friedman et al., 1995) studies confirmed the O6-BG
increases the therapeutic activity of TMZ. Accordingly, a phase II
clinical trial revealed limited benefits with high incidence of bone
marrow suppression when patients with TMZ-resistant anaplas-
tic gliomas were treated with both O6-BG and TMZ. However, it
was disappointing that no significant restoration of TMZ sensitiv-
ity occurred in patients with TMZ-resistant GBM (Quinn et al.,
2009). Because of the limited response seen in GBM patients,
alternative dosing regimens should be investigated in order to
optimize combination treatment with TMZ and O6-BG.
INTERFERON-β
Interferon-β (IFN-β), which belongs to type I IFNs, was first
discovered on the basis of its antiviral activities. Subsequently,
it was shown to exhibit pleiotropic biological activities includ-
ing immunomodulatory activity; antiangiogenic activity; and
direct antitumor effects, e.g., growth inhibition and apoptosis
(Borden et al., 2007). IFN-β markedly enhanced sensitivity to
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TMZ via downregulation of MGMT transcription (Natsume
et al., 2005; Yoshino et al., 2009). The results of the study
suggest that compared to TMZ-based chemotherapy plus
radiotherapy, chemotherapy with IFN-β and TMZ and con-
comitant radiotherapy further improve the clinical outcomes of
patients with malignant gliomas. A multicenter phase I clini-
cal trial established that therapy with IFN-β and TMZ is safe,
well tolerated, and prolongs survival of patients with GBM
(Wakabayashi et al., 2011). The median survival time (MST) of
patients who underwent the IFN-β and TMZ combination ther-
apy was significantly longer (19.9 months) than that of patients
treated with TMZ alone (12.7 months). Remarkably, the MST
of patients whose tumors had the unmethylated MGMT pro-
moter was prolonged to 17.2 months when receiving TMZ with
IFN-β, compared to 12.5 months in patients receiving TMZ
alone. Taken together, IFN-β increased the therapeutic efficiency
of TMZ in cases of newly diagnosed primary GBM, particularly
in patients with the unmethylated MGMT promoter (Motomura
et al., 2011). A prospective randomized control trial to compare
the clinical outcomes of newly diagnosed GBM patients treated
with TMZ alone or with TMZ and IFN-β combination therapy is
ongoing.
LEVETIRACETAM
Some antiepileptic drugs (AEDs) have the ability to inhibit his-
tone deacetylase (HDAC) activity. HDAC inhibitors (HDACi)
have transcriptional regulatory activity (Strahl and Allis, 2000),
suggesting that they can influence TMZ efficacy by modulat-
ing the expression of MGMT. HDACs are attractive targets in
cancer therapy because their inhibition can induce cell differenti-
ation, growth arrest, and apoptosis (Li et al., 2005). Levetiracetam
(LEV), a relatively new AED, does not directly inhibit HDAC
activity in vitro at therapeutic concentration (Eyal et al., 2004).
Instead, LEV increases the transcription of HDAC1 and recruits
the HDAC1/mSin3A corepressor complex to the p53-binding site
in the MGMT promoter (Bobustuc et al., 2010), thus silencing
MGMT (Figure 1).
In contrast, LEV increases MGMT transcription in normal
astrocytes (Bobustuc et al., 2010) and exerts a neuroprotective
FIGURE 1 | Levetiracetam increases HDAC1 transcription and recruit
HDAC1/mSin3A corepressor, which binds MGMT promoter region
intermediated by p53. This complex of three components inhibits MGMT
transcription.
role through free-radical scavenging activity (Ueda et al., 2009).
Moreover, LEV reduces the extent of inflammation and neuronal
death by inducing the expression of neurotrophic factors and
inducible nitric oxide synthase (iNOS) (Cardile et al., 2003). All
this activities may contribute to the ability of LEV to prevent
radiochemotherapy-induced nerve damage.
Taken together, TMZ-induced cytotoxicity in GBM patients
who express high levels of MGMTmay be enhanced by concomi-
tant administration of LEV with little adverse effects.
MGMT-INDEPENDENTMECHANISM
Several aspects of TMZ sensitivity cannot be explained byMGMT
promoter methylation status alone. Actually, the majority of
TMZ-induced methylation sites are the N7 position of guanine
(>70%) and N3 position of adenine (9.2%), whereas O6 methy-
lation of guanine directly removed byMGMT is the least frequent
adduct (5%). N7-methylguanine and N3-methyladenine are sub-
strates for the base excision repair (BER) system, which consists
of multicatalysis reactions by a wide variety of DNA glycosylases,
endonucleases, polymerases, and DNA ligases (Figure 2).
APNG AND GATA4
The BER enzyme, alkylpurine-DNA-N-glycosylase (APNG),
which repairs the cytotoxic lesions N3-methyladenine and
N7-methylguanine, contributes to TMZ resistance. Silencing of
APNG in TMZ-resistant GBM cell lines that express MGMT
and APNG attenuated the repair of TMZ-induced DNA damage
and enhanced apoptosis. Accordingly, exogenous expression of
APNG in TMZ-sensitive GBM lines conferred resistance to TMZ
in vitro and in vivo (Agnihotri et al., 2012), confirming that APNG
contributes to TMZ resistance in GBM.
The GATA transcription factor family consists of six members,
which bind to a consensus DNA-binding element. Recently, it was
reported that GATA4 is expressed in the embryonic and adult
central nervous system, inhibits astrocyte proliferation, and acts
as a tumor suppressor in GBM (Agnihotri et al., 2009). Loss of
GATA4, observed in the majority of GBM, was a negative prog-
nostic marker. Re-expression of GATA4 conferred sensitivity of
GBM cells to TMZ, which was independent of MGMT (Agnihotri
et al., 2011). However, GATA4 reduced the expression of APNG,
suggesting that GATA4 increases the anticancer potency of TMZ
in human GBM cells.
MPG, POLβ, PARP, NAD+ BIOSYNTHESIS
Overexpression of the BER-initiating enzyme N-methylpurine
DNA glycosylase (MPG) greatly enhances the effect of TMZ
through the imbalance of DNA repair, independent of the MGMT
status (Fishel et al., 2003; Goellner et al., 2011). Increased MPG
activity induced single-strand and double-strand breaks in DNA,
leading to apoptotic cell death (Dobson et al., 2000). However,
these effects were abrogated by elevated expression of the rate-
limiting BER enzyme DNA polymerase β (Polβ) (Tang et al.,
2011). Thus, the expression levels of MPG and Polβ in tumors
may represent biomarkers for alkylator therapy.
Poly (ADP-ribose) polymerase (PARP) is involved in DNA
repair. PARP1 particularly has the dual effect. The cytotoxic
effect of alkylating agents is enhanced by either its inhibition or
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FIGURE 2 | Two pathways of methylated DNA repair. TMZ generates a
spectrum of DNA lesions including O6-methylguanine, N3-methyladenine, and
N7-methylguanine. MGMT eliminates directly the methyl group from
O6-methylguanine, whereas BER pathway includes multistep reaction by
DNA glycosylase (APNG or MPG), endonuclease, polymerase, and DNA
ligase. DNA glycosylase recognizes and removes the damaged bases. The
abasic site is then hydrolyzed by endonuclease, resulting in the incision of the
damaged DNA strand. Polymerase inserts a single nucleotide and DNA ligase
completes the repair process. PARP, one of the polymerases of BER, catalyzes
the transfer of ADP-ribose units from NAD+ to target proteins including PARP
itself. Therefore, inhibition or hyperactivation of PARP leads to accumulation of
broken DNA or NAD+ depletion respectively, consequently inducing cell death.
hyperactivation. Inhibition of PARP1 accumulates broken DNA
in the cells, resulting in cell death (Figure 2). PARP1 is the
primary enzyme catalyzing the transfer of ADP-ribose units from
nicotinamide adenine dinucleotide (NAD+) to target proteins
including itself. Therefore, PARP1 hyperactivation leads to deple-
tion of NAD+ and ATP, which are necessary for cell metabolism,
followed by cell death (Tang et al., 2010) (Figure 2).
Inhibition of NAD+ biosynthesis also potentiates alkylator-
induced cytotoxicity (Figure 2). Therefore, dual inhibition of
BER and NAD+ biosynthesis might sensitize glioma cells to TMZ,
independent of MGMT status (Goellner et al., 2011).
RESVERATROL
Resveratrol (3,5,4′-trihydroxy-trans-stilbene) is a stilbenoid
found in the rinds of red grapes and in other fruits. It
exhibits antioxidant, anticancer, cardioprotective, and anti-aging
effects, among others. Importantly, resveratrol has been iden-
tified as a potential cancer chemopreventive agent based on
its ability to modulate cancer initiation, promotion, and pro-
gression. Resveratrol increases TMZ efficacy and although the
influence of resveratrol on MGMT is unknown, the combina-
tion of TMZ and resveratrol has a synergistic effect in vitro
and in vivo (Lin et al., 2012). TMZ induces both apoptotic
cell death and cytoprotective autophagy through a reactive
oxygen species (ROS) burst and extracellular signal-regulated
kinase (ERK) activation. Resveratrol possesses antioxidant or
pro-oxidant activity (Holme and Pervaiz, 2007). It is possible
that resveratrol suppresses TMZ-induced ROS/ERK-mediated
autophagy, resulting in increased apoptosis. These data indicate
that resveratrol may improve the efficacy of TMZ in patients with
GBM.
UNKNOWNMECHANISMS
VALPROIC ACID
Valproic acid (VPA) is a commonly prescribed AED for the treat-
ment and prevention of seizures in patients with glioma. In
addition to its antiseizure properties, VPA inhibits cell prolifer-
ation and induces differentiation and apoptosis in cancer cells
(Gottlicher et al., 2001; Li et al., 2005).
Patients with GBM who were treated with VPA appeared to
have a better outcome than did those not treated with VPA
or treated with other AEDs (Weller et al., 2011). At least four
mechanisms underlying the anti-tumor effect of VPA may be
considered. First, HDAC inhibition by VPA promotes histone
acetylation that loosens up the chromatin structure, consequently
increasing DNA accessibility to anticancer drugs such as TMZ and
enhancing the effect of γ-radiation (Van Nifterik et al., 2012).
Second, concurrent treatment with VPA and TMZ synergisti-
cally induces apoptosis in vitro independent of the p53 status
(Chen et al., 2011). Third, VPA induces autophagy, which is a
caspase-independent process characterized by the accumulation
of autophagic vacuoles in the cytoplasm, accompanied by exten-
sive degradation of organelles (Fu et al., 2010). VPA sensitizes
melanoma cells to TMZ in vitro and in vivo by activating the
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apoptotic cascade. This effect is significantly increased by INF-β
(Roos et al., 2011). Fourth, VPA increases the bioavailability of
TMZ by reducing the clearance of the metabolite that methylates
DNA (www.temodar.com).
Therefore, VPA may affect the survival of glioma patients via
different pathways.
RIBONUCLEOTIDE REDUCTASE INHIBITORS
Biosynthesis of deoxyribonucleotides (dNTP) from ribonu-
cleotides is an essential step in DNA synthesis and cell replica-
tion. Ribonucleotide reductase (RR), the rate-limiting enzyme
of this pathway, appears to be a negative predictive factor
in patients with cancer (Jordheim et al., 2011). Several drugs
that inhibit RR, such as hydroxyurea, gemcitabine, and flu-
darabine are used for the treatment of a variety of cancers.
Among the RR inhibitors, didox (DX), and trimidox (TX) are
the most potent enzyme inhibitors that demonstrated excel-
lent anticancer activity in animal tumor models (Fritzer-Szekeres
et al., 2000) and enhanced alkylator-induced cytotoxicity in vitro
(Horvath et al., 2004). Depletion or imbalance of dNTPs by
RR inhibitors may potentiate TMZ-induced cytotoxicity inde-
pendent of the p53 status (Figul et al., 2003). Since most
gliomas have a defective p53-mediated pathway, the ability of
RR inhibitors to induce apoptosis in a p53-independent man-
ner is an asset (Dehais et al., 2006; Masica and Karchin,
2011). In addition, RR inhibitors may enhance the radiosensi-
tivity of the tumor by inducing G1/S arrest and/or by inhibit-
ing DNA repair (Barker et al., 2006; Zuckerman et al., 2011).
Inhibition of DNA synthesis by RR inhibitors may increase the
time available for DNA repair in response to TMZ-mediated
damage.
In addition to synergistic cytotoxicity, DX and TX can decrease
the optimal dose of TMZ (Figul et al., 2003), thereby reducing
potential adverse effects, such as myelosuppression.
PROSPECTIVE
Recent investigations have increased the understanding of the
pharmacological mechanisms of TMZ. It is likely that drugs and
mechanisms other than those discussed above modulate TMZ
efficacy. One such mechanism is the inhibition of GSK3β, which
is a serine/threonine kinase that is overexpressed and activated
in GBM. We have previously reported that GSK3β inhibitor sen-
sitized GBM cells to TMZ-induced apoptosis in vitro via an
unknown mechanism (Miyashita et al., 2009). Notably, VPA has
been shown to inhibit the activity of GSK3β (Chen et al., 1999),
suggesting that GSK3β inhibition is one of the mechanisms by
which VPA enhances the therapeutic efficiency of TMZ.
At present, TMZ plays a central role in the treatment of GBM.
Future studies on the drugs that enhance TMZ activity without
side effects are warranted, as adjuncts to standard chemotherapies
can improve therapeutic benefit and prolong survival.
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